The ability to resist complement differs between the Y and Colombiana Trypanosoma cruzi strains. We found that the Y strain of T. cruzi was more able to resist the classical and lectin pathways of complement activation than the Colombiana strain. The complement C2 receptor inhibitor trispanning gene (CRIT) is highly conserved in both strains. At the protein level, CRIT is expressed only in stationary-phase epimastigotes of the Y but not the Colombiana strain and is expressed in infectious metacyclic trypomastigotes of both strains. Y strain epimastigotes with an overexpressed CRIT gene (pTEX-CRIT) had higher survival in normal human serum (NHS). Overexpression of the Y strain CRIT gene in Colombiana epimastigote forms increased the parasite's resistance to lysis mediated by the classical and lectin pathways but not to lysis mediated by alternative pathways. CRIT involvement on the parasite surface was confirmed by showing that the lytic activity of NHS against epimastigotes could be restored by adding excess C2.
Trypanosoma cruzi is a protozoan parasite that causes Chagas disease and that affects 18 million people in Latin America, with 90 million at risk of infection worldwide [1] . Approximately 30% of individuals in the indeterminate stage, in which parasitemia is undetectable and patients remain asymptomatic, progress to the chronic stage with severe sequelae, such as cardiomyopathy or gastrointestinal dysfunction [2, 3] .
T. cruzi needs to evade the host innate immune response to establish an infection and initiate disease. The first mechanism of vertebrate host defense against the parasite is the complement (C) system, which is composed of 30 serum proteins activated in a cascade that culminates in the lysis of the parasite. There are 3 C pathways leading to pathogen lysis by the membrane attack complex. The classical pathway (CP), activated by IgG/ IgM binding to pathogen, and the alternative pathway (AP), activated through C3b binding to pathogen, have been described. However, there has been little description of lectin pathway (LP) activation in trypanosomatids, via mannan-binding lectin (MBL) binding to carbohydrate on the pathogen surface [4 -8] .
During its life cycle, the parasite undergoes a series of developmentally regulated morphological and physiological changes to survive within insects and mammalian cells. Thus, vertebrate-stage parasites (blood trypomastigotes and amastigotes) and infective vector-stage parasites (metacyclic trypomastigotes) typically resist direct serum killing and can also evade ingestion or intracellular killing by a host phagocyte cell. In contrast, most noninfective vector-stage parasites (epimastigotes) are susceptible to lysis by serum and to phagocytosis and destruction by polymorphonuclear leukocytes.
The membrane changes that control the transformation of these parasites from being C sensitive to resistant are only partially understood. Pioneering studies of C-mediated lysis of trypanosomatids described antibod-ies of patients in the chronic phase responsible for CP activation and parasite killing [4, 6, 9] . Otherwise, the prevailing explanation for C activation during the infection is that parasites activate lysis through the AP, thereby lacking the involvement of antibodies, despite the deposition of C3b on the trypomastigote parasite surface [8] and parasite lysis occurring in the presence of serum depleted of factors of the AP [9] .
The mechanisms displayed by T. cruzi for avoiding the C system are refined, specific molecules having been reported as C inhibitors. Trypanosome decay-accelerating factor has been reported to bind to C component C3 and C-regulatory protein to bind to C3 and C4, thereby blocking the CP and AP [10, 11] . Other molecules have been shown to confer resistance to CP-and AP-mediated lysis, such as calreticulin, which interacts with C1q and blocks only the CP [12] , as well as gp 58/68, which inhibits the AP [13] . Recently, a receptor responsible for specific inhibition of CP activation in Schistosoma species [14] was described, a homologue of which we recently identified in T. cruzi [15] . Complement C2 receptor inhibitor trispanning (CRIT) is a transmembrane protein of 32 kDa. The N-terminal first extracellular domain (ed1) of CRIT shows sequence homology with part of the C4 ␤-chain and competes for binding to C2 [16] via its von Willebrand factor A domain [17] . In binding C2, CRIT inhibits the C1s-mediated cleavage of C2. CRIT is highly conserved in Schistosoma species, T. cruzi strains, and mammals [15] .
To have an overall understanding of the mechanism of C activation in T. cruzi infection, we need to consider the wide variety of strains described. On the basis of biological and epidemiological data, T. cruzi has been divided into 2 divergent groups or lineages. T. cruzi class I is found in the sylvatic transmission cycle, which affects mainly American marsupials and edentates [18, 19] . As an example of a class I strain, T. cruzi Colombiana is used in this study. By contrast, T. cruzi class II is found in the domestic transmission cycle and affects mainly humans; an example of a class II strain, T. cruzi Y strain is used. Several molecular markers allow the classes to be distinguished, such as the 24S␣rRNA gene, the intergenic region of tandemly repeated mini-exon gene, microsatellite DNA, and polymerase I promoter activity [19 -21] . The physiological relevance of T. cruzi divergence was recently shown when it was revealed that Ͼ87% of patients with Chagas disease have antibodies against the trypomastigote small surface antigen of T. cruzi II [22] .
Differential expression of C-regulatory genes within the divergent classes of T. cruzi has to date not been linked with the ability to resist C-mediated lysis. First, we show that C activation differs between the T. cruzi Y and Colombiana strains, as does the expression of the CRIT gene, which is expressed in a classspecific manner. We find CRIT protein expressed in the infective stage of T. cruzi and show that epimastigote transgenic parasites expressing CRIT are more resistant to C lysis, blocking the CP and LP.
METHODS

Parasites.
T. cruzi epimastigote forms of strains Y and Colombiana were cultured in liver infusion tryptose (LIT) medium supplemented with 10% fetal bovine serum at 27°C [23] . Metacyclic forms were obtained and purified as described elsewhere [23, 24] .
C-mediated lysis assay. First, 5.0 ϫ 10 5 logarithmic epimastigote forms of T. cruzi were resuspended in 100 L of fresh RPMI 1640 and mixed with 100 L of diluted normal human serum (NHS) in RPMI 1640 medium at 37°C in microcentrifuge tubes for 30 min. After incubation (30 s to 30 min), 800 L of cold RPMI 1640 was added, and the tube was placed on ice. Heat-inactivated NHS (56°C for 30 min) was used as a negative control. Surviving parasites were stained with trypan blue and quantified in a Neubauer chamber under a light microscope. For calculating the serum concentration that causes 50% lysis of parasites (serum lethal concentration [SLC]-50), parasites were incubated in 2-fold serial dilutions, ranging from undiluted to 3.12% NHS.
The kinetics of C-mediated killing was determined by incubating parasites in 25% NHS for 0.5, 1, 2.5, 5, 10, and 30 min. CP and LP inhibition were performed by incubating NHS with 10 mmol/L ethylene glycol tetraacetic acid (EGTA) and 7 mmol/L MgCl 2 .
C-mediated lysis was assayed using transgenic (pTEX and pTEX-CRIT) and wild-type parasites from the T. cruzi Y and Colombiana strains. Parasites growing in LIT medium (with 200 g/mL G418 added for transgenic parasite culture) at logarithmic phase (3 days) were used in this experiment. T. cruzi Y strain parasites were incubated with 25% NHS, whereas Colombiana strain parasites were incubated with 12.5% NHS. In certain experiments in which 0.5 g of C2 (0.02 mol/L) was added to restore the lysis of pTEX-CRIT transgenic parasites, kinetics were realized with 25% NHS (CP, LP, and AP activation).
Gene cloning and sequencing. Oligonlucleotides (5'-CCCG-GATTCATGTACGGGCCAGATAT-3' [forward] and 5'-CCC-AAGCTTTTAATTTCGATAAGCCAGT-3' [reverse]) based on CRIT DNA sequences from Schistosoma mansoni (GenBank accession number 6650015) were used to amplify a 0.85-kb fragment from T. cruzi Y strain genomic DNA by polymerase chain reaction (PCR). The PCR product was cloned into pGEM-T Easy Vector (Promega) and sequenced with T7 and T3 oligonucleotides using an ABI 3100 automated DNA sequencer. The sequence of T. cruzi Y strain was deposited in GenBank (accession no. AY464185). The genes of T. cruzi Cl Brener, Colombiana, and Dm28c were amplified by PCR from genomic DNA using oligonucleotides (5'-ATGTCTCCAAGTCTAGTG-3' [forward] and 5'-TTAACAAG-AAGAGTGAG-3' [reverse]) based on the CRIT sequence of the T. cruzi Y strain (GenBank accession nos. AF212030, AF212031, and AF212029, respectively).
Constructions and transfections. The CRIT gene from the Y strain cloned into pGEM-T Easy Vector was digested with
EcoRI and subcloned into the trypanosomatid expression vector pTEX, generating the vector pTEX-CRIT. Twenty-five micrograms of pTEX and pTEX-CRIT was used to transfect epimastigote forms of T. cruzi Y and Colombiana strains in logarithmic phase by an electroporation method described elsewhere [21] .
Western blotting. Parasites were washed in PBS, adjusted to 5.0 ϫ 10 6 parasites/L, and lysed with 0.1% Triton X-100/PBS/ protease inhibitor cocktails, as described elsewhere [13] . In brief, after SDS-PAGE and transfer to nitrocellulose, the primary antibody used was affinity-purified rabbit anti-CRIT-ed1 (1:100), as described elsewhere [14] . Immunoabsorption was performed by preincubating the anti-CRIT-ed1 with synthetic peptide ed1 [16] before incubation with the membrane.
Fluorescence-activated cell sorter (FACS) analysis. T. cruzi metacyclic trypomastigotes (2.0 ϫ 10 5 parasites) were incubated with 1 g of C2 for 1 h at 4°C. After that, parasites were washed 2 times with PBS and incubated with fluorescein isothiocyanate (FITC)-conjugated anti-C2 antibody, diluted 1:10 in PBS-1% bovine serum albumin, for 2 h at 4°C. IgG-FITC was used as an isotype control. Parasites were then washed 3 times and analyzed by flow cytometry using the Guava EasyCyte ExpressPlus System (Guava Technologies).
Data presentation and statistical analysis. All data are shown as means Ϯ SDs. Groups were compared by the unpaired t test for repeated measures, using Prism software (version 5.0; GraphPad). Differences were considered statistically significant at P Ͻ .05 with a confidence interval of 99%.
RESULTS
Greater susceptibility of the T. cruzi Colombiana strain than the Y strain to C-mediated lysis in the presence of NHS. Assays of C-mediated lysis were performed on epimastigote forms of T. cruzi Colombiana and Y strains, grown to the logarithmic phase, with serial dilutions of NHS to determine the serum concentration that causes SLC-50 in 30 min at 37°C.
T. cruzi Y strain epimastigote forms were lysed with NHS at concentrations of 6.25% and above, and the SLC-50 was between 25% and 50%. However, the Colombiana strain needed only as little as 3.12% NHS, and the SLC-50 was between 6.25% and 12.5% (figure 1). T. cruzi Colombiana was more susceptible to C lysis than T. cruzi Y at all serum concentrations, being 8-fold more lysed than the Y strain at 25% NHS.
The kinetics of C pathway-mediated lysis in T. cruzi Colombiana and Y strains. The kinetics of C-mediated lysis with NHS (CP, LP, and AP) and EGTA-treated NHS (evaluating only the AP, a calcium-independent process) showed differing de- figure 2A) . Alternatively, when kinetic assays were performed in the presence of AP alone, both parasites survived up to 30 min of lysis (figure 2B). After 2.5 and 5 min the Colombiana strain showed 68% and 56% survival, respectively, where the Y strain showed significantly higher levels after the same intervals (90% and 78% survival, respectively) ( figure 2B) .
Cloning of CRIT, inhibitor of the CP and LP, in T. cruzi strains. Having described a C2 inhibitory receptor, CRIT [13, 15] , in S. mansoni and Schistosoma haematobium parasites, we used oligonucleotides based on S. haematobium CRIT sequences to amplify from the genomic DNA of the T. cruzi Y strain. The PCR product was amplified and cloned into the pGEM-T Easy Vector for sequencing. The sequence shares a high nucleotide similarity with CRIT described in Schistosoma species. BLAST analysis at the amino acid level showed similarities of 97% and 96% with S. mansoni and S. haematobium CRIT, respectively [15] .
The CRIT gene was also amplified by PCR from genomic DNA of T. cruzi strains Cl Brener, Colombiana, and Dm28c. The PCR fragments were sequenced and found to share a high similarity with CRIT from the T. cruzi Y strain, Schistosoma species, and mammals. At the amino acid level, the similarity between CRIT from T. cruzi Cl Brener, Colombiana, and Dm28c strains compared with T. cruzi Y strains was Ͼ90% ( figure 3A) . The CRIT sequences reveal in the N-terminal region an ed1 domain of 27 residues and in the C-terminal region (residues 224 -274) a serine-threonine-rich region. The ed1 ( figure 3A ) was shown to bind to C factor C2 and inhibit CP activation [16] . CRIT does not have an N-terminal signal peptide and possesses 3 highly hydrophobic regions predicted to form transmembrane helices that could be integrated into the parasite membrane. The predicted topology of all the CRIT proteins remains that of a type IIIb membrane protein [25] with an extracellular N-terminus and cytoplasmic C-terminal tail. All of the T. cruzi strains have an identical ed1 (figure 3B). Searching various sequence databases reveals that the cytoplasmic tail of CRIT (mammalian parasite) has homology with similar regions in receptors that are endocytosed or that have a lysosomal targeting sequence, as highlighted elsewhere [26] .
Differential expression of CRIT in T. cruzi Y and Colombiana strains. The expression of CRIT in T. cruzi Y and Co- lombiana strains was analyzed during the in vitro differentiation from epimastigote to metacyclic trypomastigote forms. Immunoblotting using anti-CRIT-ed1 (which is specific for the N-terminal domain ed1 of CRIT) showed expression in metacyclic trypomastigote forms of both strains and in stationary-but not logarithmic-phase epimastigote forms of T. cruzi Y strain (figure 4). CRIT was detected as a protein of 27-32 kDa, compared with the already-described 32-kDa CRIT protein in Schistosoma species and mammals, and this signal could be removed by adsorption of the antibody with CRIT-ed1 peptide. Apart from a homology [16] to part of the C4 ␤-chain, which is 78 kDa, the CRIT-ed1 sequence is quite specific to the CRIT family of proteins.
Resistance to C-mediated lysis conferred by overexpression of CRIT in the epimastigote form of T. cruzi. To understand the role that CRIT plays in providing resistance to C-mediated lysis in T. cruzi, the CRIT gene of the Y strain was cloned into the pTEX expression vector and overexpressed in logarithmic epimastigote forms of the T. cruzi Y and Colombiana strains ( figure  4B ). The overexpressed CRIT gene in Y and Colombiana confers an increased resistance to C-mediated lysis in NHS compared with wild-type parasites. The transgenic parasites were assayed for their ability to resist C-mediated lysis by monitoring the kinetics of lysis. T. cruzi Y strain was incubated with 25% NHS, and within 5 and 10 min a difference was detected in lysis (figure 5A). Transgenic parasites (pTEX-CRIT), after 5 min of incubation with serum, showed equal numbers of survivors, with pTEX and wild-type parasites. After 10 min, wild-type and pTEX transgenic parasites had significantly fewer survivors than pTEX-CRIT transgenic strains. When these parasites were incubated with 25% NHS treated with EGTA and MgCl 2 to inhibit the CP and LP (figure 5B), the transgenic (pTEX-CRIT), pTEX, and wild-type strains were lysed to a similar extent. This indicates that CRIT inhibits the CP and the LP but does not confer resistance to AP-mediated lysis. The overexpression of the CRIT gene of the T. cruzi Y strain in the T. cruzi Colombiana strain was thus able to confer resistance to C-mediated lysis by NHS. Incubation of Colombiana strain expressing pTEX-CRIT with 12.5% NHS after 7.5 min showed that transgenic parasites were 2-fold more resistant (2.43 ϫ 10 5 surviving parasites [49%]) compared with wild-type parasites (1.28 ϫ 10 5 surviving parasites [26%]) (figure 6 ). These data indicate that the CRIT of Y strain was functional in the Colombiana strain and that the difference in the susceptibility to lysis by C may be associated with the differential expression of specific molecules present in each strain.
Restoration of the susceptibility to lysis by exogenous C2 in transgenic parasites overexpressing CRIT. The ability of overexpressed CRIT in epimastigote Y strain to resist C-mediated lysis is directly related to C2 binding to CRIT on the parasite surface and depletion of available C2 from NHS. We performed experiments in which C2 added to NHS restored its ability to lyse epimastigotes. With the addition of 0.5 g of C2 (0.02 mol/L), the 65% survival rate of transgenic parasites (pTEX-CRIT) was reduced to 43%, comparable with the survival levels of pTEX epimastigotes (parasites transfected with vector alone) and wild-type parasites ( figure  7A) . Furthermore, C2 binding to the infective metacyclic trypomastigote form of T. cruzi was confirmed by FACS analysis (figure 7B). C2) . B, Binding of C2 to metacyclic trypomastigote forms of T. cruzi. Parasites (2.0 ϫ 10 5 ) were incubated with C2 for 1 h at 4°C followed by incubation with fluorescein isothiocyanate (FITC)-conjugated anti-C2 antibody. Analysis was done by flow cytometry using the Guava EasyCyte ExpressPlus System (Guava Technologies). IgG-FITC was used as an isotype control.
DISCUSSION
We have shown that the Colombiana and Y strains of T. cruzi, which belong to the 2 phylogenetic lineages class I and class II, respectively, differ in their capacity to resist C-mediated lysis, and we attribute this in part to the expression of CRIT. It was also our aim to investigate the expression of CRIT in epimastigote forms as they differentiate into infective metacyclic trypomastigotes.
Complement lysis assays showed that the T. cruzi Colombiana strain is more susceptible to lysis than the T. cruzi Y strain at all serum concentrations. Kinetic assays were then performed to ascertain to which pathways strains were resistant. After 2.5 and 5 min in the presence of all 3 pathways, the Colombiana strain showed survival levels of 11% and 2.6%, respectively, whereas the Y strain presented survival levels of 60% and 44.6%, respectively. However, when the kinetic assays were performed with EGTA-treated NHS, which blocked the CP and the LP, lysis was slow to occur and had similar levels between the strains, with survival still being maintained for up to 30 min. Thus, the Colombiana strain's greater susceptibility to C lysis appears to be mainly due to the CP and LP in early activation. These findings are in accordance with those of similar experiments in Leishmania species and Crithidia species [27] , which showed a rapid activation of the CP. Additionally, the involvement of the AP, supposed to be the first mechanism in C-mediated lysis in T. cruzi [7, 8, 28] , showed a minimum role in immediate lysis.
As a mechanism of C-mediated lysis in T. cruzi, which is important during the early activation of C, the LP [29, 30] has been little considered. However, in Leishmania braziliensis it was recently shown that MBL binds to surface glycoconjugates and activates the LP [5] . SA85-1, a mannose receptor found in amastigote forms of T. cruzi, binds to MBL and is involved in the uptake of the parasites into macrophages, thus increasing infection [31] . Recently, it was reported that MBL deficiency in patients increases susceptibility to infection [32, 33] .
The switch by which trypanosomatids have evolved from the epimastigote form, which is sensitive to C-mediated lysis by NHS, to the C-resistant metacyclic form is not well understood. Norris [11] showed that a C3 receptor, C-regulatory protein, was expressed in trypomastigote forms and not in insect-stage epimastigotes. The overexpression of the gene for C-regulatory protein in insect forms through transgenic parasites conferred resistance to C-mediated lysis. The mere expression of C-regulatory genes only in the metacyclic form might explain the acquired resistance to serum lysis, but other mechanisms could be involved [34] . We have found a novel C2 receptor, CRIT, expressed in infective forms of the Y and Colombiana strains of T. cruzi, providing them with resistance to C-mediated lysis by NHS. The CRIT gene is highly similar to the gene described in Schistosoma species and mammals [16] . CRIT in the Y strain possesses the N-terminal ed1, reported to bind to C2 and block the CP and the LP, and 3 transmembrane regions that could be involved in membrane insertion. The gene sequences obtained from the T. cruzi Cl Brener, Colombiana, and Dm28c strains are highly homologous to that of the Y strain, with 88%, 90%, and 98% identity, respectively.
Overexpression of the Y strain CRIT gene in the C-sensitive epimastigote forms resulted in transgenic epimastigote forms being better able to resist C-mediated lysis. The level of lysis, compared with that for wild-type parasites, decreased within the first minutes, showing that CRIT blocks the propagation of the C cascade. This effect resembles metacyclic trypomastigote resistance to C at the first contact in vertebrate hosts. Interestingly, in the presence of AP alone, the degrees of lysis were similar in epimastigotes overexpressing CRIT and in wild-type parasites, indicating that CRIT inhibits specifically the CP and the LP, as was described in Schistosoma species and their hosts. The expression of the class II CRIT gene of the Y strain in the T. cruzi Colombiana strain conferred resistance to C lysis, indicating that the gene is functional in the class I strain.
A broad set of virulence factors and invasion-associated molecules has been studied by different groups searching for qualitative and/or quantitative differences among T. cruzi class I and II strains [18] . The phenomenon of the bipolar biological behavior between classes associated with differentially expressed antigens has not been interpreted convincingly. In this work, we have seen differences at the level of C resistance between Colombiana (a class I strain) and Y (a class II strain) and found CRIT, at the protein level, to be expressed differentially in the Y strain. The lack of an effective vaccine or chemotherapeutic treatment that protects the human host against trypanosomatid invasion makes it especially important to understand the molecular basis of the differences in C activation between class I and II strains and thereby, it is hoped, to find putative new targets to control the disease. The characterization of CRIT, a novel C-inhibiting protein, could be key to elaborating a new chemotherapeutic or vaccine-based strategy and to understanding the biological differences between class I and II strains.
